ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

biogen netherlands b.v. - natalisumab - hulgiskleroos - selektiivsed immunosupressandid - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ja 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuuria, paroksüsmaalne - selektiivsed immunosupressandid - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - leflunomiid - artriit, reumatoidartriit - selektiivsed immunosupressandid - leflunomiidi on näidustatud ravi täiskasvanud patsientidel:aktiivse reumatoidartriidi kui "haigust moduleeriva reumavastased uimasti" (dmard). hiljutine või samaaegne ravi hepatotoxic või haematotoxic dmards e. metotreksaat) võib põhjustada suurenenud risk raskete kõrvaltoimete, seega algatamise leflunomiidi ravi on hoolikalt tuleb kaaluda seoses nimetatud kasu / riski aspekte. lisaks sellele üleminek leflunomiidi teise dmard ilma pärast washout menetluse võib suureneda ka risk tõsiste kõrvaltoimete isegi pikka aega pärast lülitus.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

novartis europharm limited  - siponimod fumaarhape - sclerosis multiplex, relapsing-remitting - selektiivsed immunosupressandid - mayzent on näidustatud ravi täiskasvanud patsientidel, kellel on sekundaarse progresseeruva sclerosis multiplex (spms) aktiivne haiguse tõendab ägenemiste või kujutise omadused põletikuline aktiivsus.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomide - hulgiskleroos - selektiivsed immunosupressandid - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

takeda pharma a/s - vedolizumab - colitis, ulcerative; crohn disease - selektiivsed immunosupressandid - haavandiline colitisentyvio on näidustatud ravi täiskasvanud patsientidel mõõduka kuni raske aktiivse haavandilise koliidi, kes on ebaadekvaatne reaktsioon, kadunud vastuse, või olid sallimatu kas tavalise ravi või tuumori nekroosi faktor α (tnfa) antagonist. crohni diseaseentyvio on näidustatud ravi täiskasvanud patsientidel mõõduka kuni raske aktiivse crohni tõbi, kes on ebaadekvaatne reaktsioon, kadunud vastuse, või olid sallimatu kas tavalise ravi või tuumori nekroosi faktor α (tnfa) antagonist. pouchitisentyvio is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

pfizer limited - celecoxib - adenomatoos polyposis coli - antineoplastilised ained - onsenal on näidustatud adenomatoossete soolepolüüpide perekondliku adenomatoosse polüpoosi (fap) arvu vähendamise dieedile operatsiooni ja edasise endoskoopiline järelevalve (vt lõik 4. mõju onsenal-indutseeritud vähendamine polyp koormust oht soolestiku vähi ei ole tõestatud (vt lõigud 4. 4 ja 5.

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

inteli generics nord uab - tselekoksiib - kõvakapsel - 200mg 30tk; 200mg 40tk; 200mg 10tk; 200mg 100tk; 200mg 60tk; 200mg 20tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

inteli generics nord uab - tselekoksiib - kõvakapsel - 100mg 100tk; 100mg 40tk; 100mg 20tk; 100mg 10tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

vetoquinol s.a. - tsefaleksiin - tablett - 750mg 6tk; 750mg 72tk; 750mg 150tk